Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Successes in frozen ovarian tissue technology may offer hope to women being treated for cancer

Doctors in Denmark have succeeded in producing a two-cell embryo after ovarian tissue was removed, frozen, and then thawed and replaced two years later.

29 Jun 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

Tommy G. Thompson has announced a new Medicare program that will save seniors and the disabled substantial money

HHS Secretary Tommy G. Thompson today announced a new Medicare demonstration program that will save seniors and persons with disabilities substantial money

24 Jun 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

New drugs ease treatment of multiple myeloma

Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.

10 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Cancer rates falling in the US

The nation's leading cancer organizations report that Americans' risk of getting and dying from cancer continues to decline and survival rates for many cancers continue to improve.

3 Jun 2004

Umbilical cord blood and bone marrow transplants slow the progression of many cancers

Umbilical cord blood and bone marrow transplants at Loyola University Health System, Maywood, Ill., are curing or slowing the progression of many cancers originating in the bone marrow (i.e., leukemia, myeloma) or lymphatic system (lymphoma).

3 Jun 2004

Higher rate of cancer in meat industry

A study of over 6600 meat industry workers around New Zealand has found a significantly high rate of cancers, particularly lung cancer, which may be caused by exposure to cancer causing agents carried by animals.

31 May 2004

Cigarette smoking linked to leukemia

Cigarette smoking has been linked to acute myelogenous leukemia, according to The Health Consequences of Smoking: A Report of the Surgeon General, released today.

27 May 2004

Scientists have genetically engineered a mouse with extraordinary resistance to bowel cancer

Scientists have genetically engineered a mouse with extraordinary resistance to bowel cancer, delegates at the Cancer Research UK senior researchers' conference in Harrogate will hear today.

24 May 2004

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation and survive can expect full recovery to take 3-5 years

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation (HCT) and survive can expect full recovery to take 3-5 years, according to a study published in the May 19 issue of The Journal of the American Medical Association (JAMA).

19 May 2004

Cancer-causing gene identified that may play a key role in the development of leukemia and other cancers

Using genetically engineered mice, researchers at the Johns Hopkins Children's Center have identified a gene that functions as a cancer-causing gene (or oncogene) and may play a key role in the development of leukemia and other cancers in children and adults.

15 May 2004

Bone marrow and stem cell transplantation rejection averted by UV light exposure

One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.

10 May 2004

Discovery of molecular switch could lead to new treatments for lymphoma and other forms of cancer

Turning a vital component of cancer cells from bodyguard to assassin could form the basis of new cancer treatments, according to a report published this week.

4 May 2004

Scientists identify six genes associated with the most common form of non-Hodgkin's lymphoma

In a paper that will be published on Thursday, April 29, 2004 in the New England Journal of Medicine, a team of scientists from Stanford University and Applied Biosystems, an Applera Corporation business, describe the identification of six genes associated with survival in diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin's lymphoma.

28 Apr 2004

Experimental immune-boosting drug interleukin-2 helps HIV Patients

National Institutes of Health (NIH) scientists report that brief, widely-spaced courses of the experimental immune-boosting drug interleukin-2 (IL-2) allow people with HIV to maintain near normal levels of a key immune system cell for long periods.

26 Apr 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

Tibetan yoga helps cancer and insomnia

The first study to look at the use of Tibetan yoga by cancer patients found the combination of movement and meditation led to a significant sleep benefit, say researchers at The University of Texas M. D. Anderson Cancer Center.

16 Apr 2004

Drug duo prevents life-threatening condition in children undergoing stem cell transplant

A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant

14 Apr 2004